Xue-Qing Wei1, Xing Li, Xiao-Jie Xin, Zhong-Sheng Tong, Sheng Zhang. 1. Department of Ultrasonic Diagnosis and Treatment, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China E-mail : dr.zhangsheng@yahoo.cn.
Abstract
OBJECTIVES: To compare the clinicalpathological features and prognosis between premenopausal breast cancer patients aged of <35 and ≥35 years old. METHODS: The clinical data and survival status of 1498 cases premenopausal operable breast cancer treated in our hospital from 2002.1 to 2004. 12 were collected, 118 cases were aged <35. They were divided into 4 groups: Luminal A, Luminal B, HER2-positive, Triple-negative. The disease free survival (DFS) and overall survival (OS) were identified. RESULTS: The 5-year DFS and OS rates were significantly lower in age<35 than in age≥35 patients. In the Luminal B, HER2-positive, Triple-negative group, the 5-year recurrence risk was higher in age<35 than in age≥35 patients, and age<35 patients' 5-year death risk was higher only in Luminal B, Triple-negative group. Regardless of whether lymph node involved, age<35 patients had a bad prognosis in both DFS and OS. CONCLUSIONS: Compared with premenopausal age ≥35 breast cancer, age<35 patients had a worse outcome.
OBJECTIVES: To compare the clinicalpathological features and prognosis between premenopausal breast cancerpatients aged of <35 and ≥35 years old. METHODS: The clinical data and survival status of 1498 cases premenopausal operable breast cancer treated in our hospital from 2002.1 to 2004. 12 were collected, 118 cases were aged <35. They were divided into 4 groups: Luminal A, Luminal B, HER2-positive, Triple-negative. The disease free survival (DFS) and overall survival (OS) were identified. RESULTS: The 5-year DFS and OS rates were significantly lower in age<35 than in age≥35 patients. In the Luminal B, HER2-positive, Triple-negative group, the 5-year recurrence risk was higher in age<35 than in age≥35 patients, and age<35 patients' 5-year death risk was higher only in Luminal B, Triple-negative group. Regardless of whether lymph node involved, age<35 patients had a bad prognosis in both DFS and OS. CONCLUSIONS: Compared with premenopausal age ≥35 breast cancer, age<35 patients had a worse outcome.
Authors: Li-Chen Tang; Xi Jin; Hai-Yuan Yang; Min He; Helena Chang; Zhi-Ming Shao; Gen-Hong Di Journal: BMC Cancer Date: 2015-03-29 Impact factor: 4.430
Authors: Tomasz Kostrzewa; Kamlesh K Sahu; Magdalena Gorska-Ponikowska; Jack A Tuszynski; Alicja Kuban-Jankowska Journal: Drug Des Devel Ther Date: 2018-12-05 Impact factor: 4.162
Authors: Charny Park; Kyong-Ah Yoon; Jihyun Kim; In Hae Park; Soo Jin Park; Min Kyeong Kim; Wooyeong Jang; Soo Young Cho; Boyoung Park; Sun-Young Kong; Eun Sook Lee Journal: Cancer Sci Date: 2019-04-02 Impact factor: 6.716